# Cellarity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellarity

- Industry: Biotechnology
- Headquarters: Somerville, US
- Website: www.cellarity.com
- Total disclosed funding: $248M
- Latest round: Series C (Aug 4, 2022)
- Investors on record: 6

## About

Based in the US, Cellarity, Inc. is a biotechnology company focused on revolutionizing drug discovery through its unique platform that combines artificial intelligence and single-cell omics data to develop targeted therapies for a variety of diseases.Founded in 2017 and headquartered in Somerville, US, Cellarity, Inc. specializes in innovative drug discovery. The company has conducted 4 deals, with its most recent funding round, Series C, occurring in August 2022, raising USD 116.060 mn led by Flagship Pioneering, and including investors like Hanwha Impact Partners and Kyowa Kirin. Nick Plugis, the founder, has a history of enterprise founding, though other companies were not specified in the available information.Cellarity specializes in a groundbreaking approach to drug discovery, primarily utilizing its innovative platform that leverages artificial intelligence and single-cell omics data. This platform integrates biological and chemical insights with multi-omics data, facilitating the development of targeted therapies aimed at addressing cellular dysfunction across a wide spectrum of diseases. By focusing on single-cell analysis, Cellarity is able to provide unparalleled insights into disease biology, enabling the design of precision medicines that traditional methods may overlook. The company targets a diverse range of end users, including pharmaceutical companies and research institutions, primarily in North America and Europe, who are seeking advanced solutions for complex health challenges.The revenue model for Cellarity is structured around partnerships and direct collaborations with pharmaceutical and biotech companies. This involves providing access to their proprietary platform and technologies, which can assist clients in the discovery and development of novel therapeutics. Transactions typically occur through agreements that may include licensing fees or milestone payments tied to specific developmental achievements or outcomes. While specific pricing details for their services are not publicly disclosed, the company’s offerings, such as their flagship platform for multi-omics drug discovery, are expected to fit within a framework that reflects the value of advanced biotechnological solutions in the pharmaceutical industry.In August 2022, Cellarity, Inc. raised USD 116.060 mn in Series C funding, which will be utilized to strengthen its platform, advance its pipeline toward the clinic, and accelerate its talent acquisition. The company is focusing on the development of new products based on its platform and plans to expand its market reach into additional regions, although specific new markets or release dates have not been detailed in the available information.

## Funding rounds

- Series C, Aug 4, 2022, $116M — Flagship Pioneering, Kyowa Kirin, Hanwha Impact Partners
- Series B, Feb 25, 2021, $123M — Flagship Pioneering, Baupost Group, BlackRock, Pictet Alternative Advisors
- Series A, Dec 10, 2019, $8.7M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C
- Baupost Group — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series B
- Kyowa Kirin — Series C
- Hanwha Impact Partners (https://capitalatlas.ai/funds/hanwha-impact-partners) — Series C